title: DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway.
abstract: Small-cell lung cancer (SCLC) is the most aggressive subtype of lung cancer in its clinical behavior, with a 5-year overall survival as low as 5%. Despite years of research in the field, molecular determinants of SCLC behavior are still poorly understood, and this deficiency has translated into an absence of specific diagnostics and targeted therapeutics. We hypothesized that tumor DNA copy number alterations would allow the identification of molecular pathways involved in SCLC progression. Array comparative genomic hybridization was performed on DNA extracted from 46 formalin-fixed paraffin-embedded SCLC tissue specimens. Genomic profiling of tumor and sex-matched control DNA allowed the identification of 70 regions of copy number gain and 55 regions of copy number loss. Using molecular pathway analysis, we found a strong enrichment in these regions of copy number alterations for 11 genes associated with the focal adhesion pathway. We verified these findings at the genomic, gene expression and protein level. Focal Adhesion Kinase (FAK), one of the central genes represented in this pathway, was commonly expressed in SCLC tumors and constitutively phosphorylated in SCLC cell lines. Those were poorly adherent to most substrates but not to laminin-322. Inhibition of FAK phosphorylation at Tyr(397) by a small-molecule inhibitor, PF-573,228, induced a dose-dependent decrease of adhesion and an increase of spreading in SCLC cell lines on laminin-322. Cells that tended to spread also showed a decrease in focal adhesions, as demonstrated by a decreased vinculin expression. These results support the concept that pathway analysis of genes in regions of copy number alterations may uncover molecular mechanisms of disease progression and demonstrate a new role of FAK and associated adhesion pathways in SCLC. Further investigations of FAK at the functional level may lead to a better understanding of SCLC progression and may have therapeutic implications.
authors.affiliation: Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University, Nashville, TN 37232-6838, USA.
authors.forename: S
authors.initials: S
authors.lastname: Ocak
authors.forename: H
authors.initials: H
authors.lastname: Yamashita
authors.forename: A R
authors.initials: AR
authors.lastname: Udyavar
authors.forename: A N
authors.initials: AN
authors.lastname: Miller
authors.forename: A L
authors.initials: AL
authors.lastname: Gonzalez
authors.forename: Y
authors.initials: Y
authors.lastname: Zou
authors.forename: A
authors.initials: A
authors.lastname: Jiang
authors.forename: Y
authors.initials: Y
authors.lastname: Yi
authors.forename: Y
authors.initials: Y
authors.lastname: Shyr
authors.forename: L
authors.initials: L
authors.lastname: Estrada
authors.forename: V
authors.initials: V
authors.lastname: Quaranta
authors.forename: P P
authors.initials: PP
authors.lastname: Massion
mesh_terms: D018288:Carcinoma, Small Cell / Q000235:genetics* / Q000473:pathology; D002448:Cell Adhesion; D045744:Cell Line, Tumor; D055028:Comparative Genomic Hybridization; D051416:Focal Adhesion Protein-Tyrosine Kinases / Q000032:analysis / Q000037:antagonists & inhibitors / Q000502:physiology; D022001:Focal Adhesions; D018628:Gene Dosage; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology; D015363:Quinolones / Q000494:pharmacology; D013450:Sulfones / Q000494:pharmacology
chemical_list: C521108:6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; D015363:Quinolones; D013450:Sulfones; D051416:Focal Adhesion Protein-Tyrosine Kinases
references.citation: Cancer Res. 1994 Oct 1;54(19):5086-91
references.pmid: 7923122
references.citation: Cell Regul. 1991 Nov;2(11):951-64
references.pmid: 1725602
references.citation: Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W741-8
references.pmid: 15980575
references.citation: Lung Cancer. 2004 Oct;46(1):11-9
references.pmid: 15364128
references.citation: Nat Cell Biol. 2004 Feb;6(2):154-61
references.pmid: 14743221
references.citation: Cancer Sci. 2005 Oct;96(10):661-7
references.pmid: 16232197
references.citation: Mol Cancer Res. 2006 Oct;4(10):709-14
references.pmid: 17050665
references.citation: Mol Cancer Res. 2007 Apr;5(4):331-9
references.pmid: 17426248
references.citation: Mol Carcinog. 2007 Jun;46(6):488-96
references.pmid: 17219439
references.citation: Am J Pathol. 1979 Jul;96(1):5-20
references.pmid: 37740
references.citation: Hum Pathol. 1998 Oct;29(10):1145-9
references.pmid: 9781656
references.citation: Respirology. 2006 May;11(3):241-8
references.pmid: 16635081
references.citation: Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3233-7
references.pmid: 16740741
references.citation: Cancer Res. 2008 Mar 15;68(6):1935-44
references.pmid: 18339875
references.citation: Nat Rev Mol Cell Biol. 2005 Jan;6(1):56-68
references.pmid: 15688067
references.citation: Nat Biotechnol. 2000 Sep;18(9):1001-5
references.pmid: 10973224
references.citation: Annu Rev Cell Dev Biol. 1995;11:549-99
references.pmid: 8689569
references.citation: Cancer Res. 2002 Jul 1;62(13):3636-40
references.pmid: 12097266
references.citation: PLoS Med. 2005 Nov;2(11):e313
references.pmid: 16187797
references.citation: Oncogene. 2006 Jan 5;25(1):130-8
references.pmid: 16116477
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: Cancer Res. 1992 Mar 1;52(5):1322-8
references.pmid: 1346589
references.citation: Cancer Res. 1995 Jul 1;55(13):2752-5
references.pmid: 7796399
references.citation: J Biol Chem. 2007 May 18;282(20):14845-52
references.pmid: 17395594
references.citation: Lancet. 2005 Oct 15-21;366(9494):1385-96
references.pmid: 16226617
references.citation: Mol Cancer Ther. 2009 Jan;8(1):101-9
references.pmid: 19139118
references.citation: Int J Oncol. 2006 Sep;29(3):567-75
references.pmid: 16865272
references.citation: Cancer Genet Cytogenet. 1987 Jul;27(1):45-50
references.pmid: 3034398
references.citation: Oncogene. 2002 Oct 7;21(45):6877-83
references.pmid: 12362270
references.citation: Cancer Res. 2008 Mar 15;68(6):1647-55
references.pmid: 18339843
references.citation: J Cell Biol. 1992 Nov;119(4):893-903
references.pmid: 1385444
references.citation: J Cell Physiol. 2007 Dec;213(3):589-602
references.pmid: 17786953
references.citation: Cancer Res. 2003 Nov 1;63(21):7113-21
references.pmid: 14612504
references.citation: Nat Genet. 1998 Oct;20(2):207-11
references.pmid: 9771718
references.citation: Br J Cancer. 2006 Jun 19;94(12):1927-35
references.pmid: 16705311
references.citation: Cancer Res. 2005 Jul 1;65(13):5561-70
references.pmid: 15994928
references.citation: Cancer Metastasis Rev. 2003 Dec;22(4):359-74
references.pmid: 12884911
references.citation: J Cell Sci. 2003 Apr 15;116(Pt 8):1409-16
references.pmid: 12640026
references.citation: Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9
references.pmid: 11707590
references.citation: Bioinformatics. 2003 Jan 22;19(2):185-93
references.pmid: 12538238
references.citation: Front Biosci. 2003 May 01;8:d982-96
references.pmid: 12700132
references.citation: Cancer Res. 1994 Apr 1;54(7):1801-6
references.pmid: 8137295
references.citation: J Clin Oncol. 2003 Oct 15;21(20):3798-807
references.pmid: 12953099
references.citation: J Natl Cancer Inst. 2005 May 4;97(9):643-55
references.pmid: 15870435
references.citation: BMC Bioinformatics. 2005 Mar 24;6:72
references.pmid: 15790402
references.citation: Am J Respir Crit Care Med. 2008 Dec 1;178(11):1164-72
references.pmid: 18776155